10x Genomics, Inc. TXG Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number?
- 10x Genomics, Inc. (TXG) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested number of $7.98M in Q1 2026.
- How has 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number changed year-over-year?
- 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number increased by 4.6% year-over-year, from $7.62M to $7.98M.
- What is the long-term trend for 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested number has grown at a 56.9% compound annual growth rate (CAGR), from $823.95K to $7.83M.